GUCY2C and Parkinson disease: Together, these findings offer compelling evidence that cyclic nucleotide-mediated signaling, whether through PDE inhibition or GUCY2C activation, holds promise as a novel therapeutic avenue for addressing striatal dopamine deficiency in neurodegenerative disorders such as Parkinson’s disease.